AACR 2024 | Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II study
Pau Abrisqueta
• 5 Apr 2024
Pau Abrisqueta, MD, PhD, Vall d´Hebron University Hospital, Barcelona, Spain, briefly comments on the findings of a Phase Ib/II study (NCT02600897) investigating the use of polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares the rationale for assessing this combination of agents. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
